People Living With HIV

Since its establishment in 1987, thousands of people living with HIV have participated in clinical trials at the Case ACTU. Their participation led directly to the development of effective and better treatments for HIV infection. Many of the clinical trials offered at the Case ACTU are through its affiliation with the AIDS Clinical Trials Group (www.actgnetwork.org). At any given point in time, the Case ACTU has several trials enrolling HIV-positive people for a variety of new medicines and treatments.

To receive more information or for questions regarding AIDS clinical trials at Cleveland Medical Center, call Jane Baum at 216-844-2546 or email baum.jane@clevelandactu.org

 


 Protocol Summary:  This is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding maraviroc (MVC) and dolutegravir (DTG) to the current antiretroviral therapy (ART) of HIV-infected individuals who have at least mild neurocognitive impairment with a primary outcome of improvement in neurocognitive performance. Purpose of This […]

A5324: To see if adding extra anti-HIV medicines reduces HIV-associated ...


Protocol Summary and Purpose of this Study:   This is a randomized, open-label, two-arm (phase IIa) study of ruxolitinib in HIV-infected adults. Eligible participants on select antiretroviral therapy (ART) with virologic suppression will be randomized to receive ruxolitinib or no study treatment to measure safety, tolerability, PK and to determine whether […]

A5336: A Study of Ruxolitinib in ART-Treated HIV-1 Infected Adults




A clinical trial of low-dose methotrexate on inflammation in HIV-infected people who are at risk for cardiovascular disease (CVD): A5314. https://actgnetwork.org/study/a5314-mtx-hiv-positives Brief Summary and Purpose of this study: Anti-HIV medicines have been very successful in allowing people with HIV to control the virus. However, researchers have noticed that many patients have […]

A5314: Effects of methotrexate on inflammation in poz folks at ...